One Adjuvant. Two Missions.
HOHO Biotech’s proprietary HRCC (Hydrogen-Rich Coral Calcium) delivers sustained molecular hydrogen from the gut. In defense, it powers Dual-Spectrum Combat Enhancement. In medicine, it is designed for patients in treatment, and for promising new medicines that would otherwise fail on toxicity.
Taiwan FDA-registered
Founded with a commitment to evidence-based molecular science, HOHO Biotech bridges cutting-edge biomedical research and practical healthcare applications.
While molecular hydrogen has long been recognized for its selective physiological benefits, conventional delivery methods have faced severe limitations in stability, duration, and systemic delivery.
HOHO Biotech overcomes these challenges through our proprietary HRCC (Hydrogen-Rich Coral Calcium) platform. By engineering a sustained gut-release mechanism, HRCC stabilizes intestinal hydrogen circulation, allowing molecular hydrogen to act as a sustainable physiological adjuvant — one that supports the body under stress rather than replacing existing care.
We advance this platform along two missions. In defense, we aim to sustain combat power in an era of attrition warfare. In medicine, we study HRCC alongside therapies.
Backed by peer-reviewed cell, animal and human studies, an international patent portfolio and proprietary manufacturing processes, we work with military hospitals, research institutions and clinical centers in Taiwan and worldwide.
Publications
Extensive academic validation across leading international biomedical journals.
& Cell Studies
Ongoing cell, animal and human studies led by our 30+ physician-scientist network across Taiwan, Japan and the United States.
Technology
Named one of the Global Top 8 in the Defense Technology category at SelectUSA 2026.
Alliances
Active translational research collaborations with prestigious medical centers worldwide.
One Adjuvant. Two Missions.
Dual-Spectrum Combat Enhancement
Modern wars are wars of attrition: the side that keeps its combat power — and denies the enemy theirs — wins. HRCC is a ration-ready hydrogen capsule.
Spectrum 2 · Protection — Preserve combat power
Every trained operator is a strategic asset. HRCC is designed to buffer the oxidative stress of sleep deprivation, extreme exertion, blast and radiation exposure, keeping units mission-capable across repeated deployments — a role for hydrogen studied by Japan’s National Defense Medical College, the Czech University of Defence, the U.S. Navy and NASA.
Field-ready today, not someday: shelf-stable, ration-ready, no devices.
Global Top 8, Defense Technology category, SelectUSA 2026 · Formulations in development; performance claims under evaluation.
Less Drug Harm
Many effective therapies carry a hidden cost: oxidative stress and inflammation that burden the liver, kidneys and gut. As a sustainable adjuvant, HRCC is designed to be taken alongside existing treatment — never as a replacement — to help the body buffer drug- and toxin-induced oxidative injury.
- Cell & animal — Reduced indoxyl sulfate-induced ROS and NLRP3 inflammasome activation in renal fibrosis models (Eur J Pharmacol 2025 · 20250810).
- Animal — Improved alcohol intoxication outcomes in mice (20220629); modulated gut microbiome and bile acids in a fatty-liver model (20240620).
- Human — Safety and lipid profile in metabolic syndrome (20230714); microinflammation markers in a pilot observational study (20240718).
- Ongoing — A prospective study in rheumatoid arthritis at Taoyuan Armed Forces General Hospital.
- Case reports — Methotrexate-induced myelosuppression (20250315); immunosuppressant tapering in lupus (20260327); multiple drug intolerances (20251007).
More Drugs That Succeed
About 90% of drug candidates that enter clinical trials never reach patients, and roughly 30% of those failures are due to unmanageable toxicity.1 Many promising small molecules and vaccines are abandoned not because they don’t work, but because the body cannot handle the oxidative and inflammatory burden they create — liver and kidney toxicity, or immune-related adverse events.
HRCC is designed to be built directly into the medicine:
- Standard dose — 17 mg of HRCC per tablet or capsule (the HRCC content of our HR and HD3 formulations).
- High-concentration dose — 170 mg of HRCC (the HRCC content of our H2C formulation).
- Co-administration — one HRCC capsule taken orally alongside injectable therapies or vaccination.
Not a new ingredient to validate from scratch: HRCC is already a registered product.
Our goal: help promising candidates clear the toxicity barrier, support circulation, metabolism and gut health for better absorption, and save drug developers years and costs — so more safe medicines reach the market.
1 Sun D, Gao W, Hu H, Zhou S. Why 90% of clinical drug development fails and how to improve it? Acta Pharm Sin B. 2022;12(7):3049-62. doi:10.1016/j.apsb.2022.02.002
Published Proof of Concept
- In kidney cells injured by the toxin indoxyl sulfate, HRCC reduced ROS and NLRP3 inflammasome activation.
- Combined with the NLRP3 inhibitor MCC950 or the antioxidant drug N-acetylcysteine, HRCC produced a stronger effect than HRCC alone — working with drugs, not against them.
- In mice, HRCC reduced kidney fibrosis in a dose-dependent manner, while high-dose HRCC alone did not alter healthy kidneys. The authors describe HRCC as a potential adjuvant intervention.
- The same ROS–NLRP3 pathway drives the kidney toxicity of widely used drugs such as cisplatin — the next step in our pharma partnership program.
Wu TK, Hsieh YH, Hung TW, Chiou HL, Shih HY, Ting YH, et al. Coral Hydrate improves renal fibrosis by inhibiting indoxyl sulfate-induced ROS-mediated NLRP3 inflammasome activation. Eur J Pharmacol. 2025;1008:178367. doi:10.1016/j.ejphar.2025.178367 · 20250810
These statements have not been evaluated by the U.S. Food and Drug Administration. HRCC products are not intended to diagnose, treat, cure, or prevent any disease.
Already Trusted in Clinical Practice
Everything we describe is not a research project. HRCC and HRCC-based capsules are mature, registered products already in daily use across Taiwan, with a safety profile backed by peer-reviewed studies and years of real-world clinical use.
Where HRCC is used today
Medical centers · Regional hospitals · Medical-aesthetics clinics · Anti-aging clinics · Traditional Chinese Medicine clinics · National pharmacy chains · Independent pharmacies
Names of partner hospitals and pharmacies are withheld under confidentiality agreements.
To sustain those who fight and those who heal through sustainable molecular hydrogen technology.
To become the global reference platform for sustainable hydrogen adjuvant science.
Grounded in peer-reviewed cell, animal and human studies, and reproducible translational research.
Bridging fundamental biochemistry with practical, highly stable bio-delivery systems.
Committed to transparent collaboration, global regulatory standards, and verifiable data.
Designing sustainable, long-term health solutions that empower human adaptability.
Stabilizing Gut Hydrogen Circulation
HOHO Biotech’s core breakthrough centers on stabilizing intestinal hydrogen circulation through our proprietary HRCC platform. Unlike short-lived dissolved hydrogen water or gas inhalation, HRCC provides sustained, targeted release within the gastrointestinal tract. This steady micro-environment continuously supplies molecular hydrogen into the mesenteric circulation and portal system. Acting as a sustainable physiological adjuvant, the platform is being studied for its role in cellular redox homeostasis and its use alongside medications, nutraceuticals and field rations.
Core Capabilities
Proprietary HRCC Platform
Engineered mineral lattice matrix providing prolonged, stable, and localized molecular hydrogen generation within the digestive tract.
Translational Clinical Pipeline
Robust collaboration with medical research institutes, conducting rigorous human trials and preclinical studies to validate physiological mechanisms.
Scalable GMP Capacity & Patented Bioprocess
Scalable, GMP-compliant manufacturing that can expand capacity 10× to 100× and deliver within 4–6 months. Formulation, release control and processing methods are protected by U.S. and PCT patent applications.
Global Regulatory Compliance
Comprehensive analytical characterization and strict quality assurance protocols meeting international safety standards for food, nutraceutical, and biomedical integration.
Selected Milestone Publications
Published by our physician-scientist network spanning Taiwan, Japan and the United States — with studies from northern, central and southern Taiwan and the U.S., and new work underway in Japan.
- 2026
FEATUREDAntioxidants (Review) 20260908
Molecular hydrogen and the uremic skeleton: a critical review and redox hypothesis in CKD–mineral and bone disorder.
- 2025
FEATUREDEuropean Journal of Pharmacology 20250810
Cell & animal study: HRCC protects kidney cells from toxin-induced injury by reducing ROS and NLRP3 inflammasome activation.
- 2024
FEATUREDAntioxidants 20240620
Animal study: HRCC reshapes the gut microbiome and bile acid synthesis to improve fatty liver.
- 2024
International Journal of Medical Sciences 20240718
Human pilot study: oral molecular hydrogen supplements and microinflammation.
- 2023
Frontiers in Nutrition B 20230714
First in Human study: safety and lipid-lowering potential of HRCC capsules in patients with metabolic syndrome.
Milestones
- 2026
Named one of the Global Top 8 in the Defense Technology category at SelectUSA 2026, the investment summit hosted by the U.S. government in the Washington, D.C. area.
- 2026
Critical review on molecular hydrogen in CKD–mineral and bone disorder published in Antioxidants (20260908); the monograph Unleashing the Therapeutic Power of Hydrogen will soon be available as an e-book.
- 2025
Cell & animal study in European Journal of Pharmacology (20250810); PCT patent application filed.
- 2024
Additional Taiwan FDA product registration; human pilot study (20240718) and gut-microbiome study (20240620); U.S. patent application filed.
- 2023
First in Human study in Frontiers in Nutrition (20230714).
- 2021
Second Taiwan FDA product registration.
- 2020
Taiwan FDA product registration obtained; HRCC hydrogen capsules launched in Taiwan.
- 2017
HOHO Biotech founded in Taipei; HRCC formulation R&D begins.
Management Team · HOHO Biotech
Medical, pharmaceutical, patent and industry experts across Taiwan, the United States and Japan.
KOMATSU RIKOJapan
Frank L. Douglas, Ph.D., M.D.Former EVP & Chief Scientific Officer, AventisUSA
Hsiu-Ming Saunders, Ph.D., J.D.Founder, IPC Intellectual Property ConnectionsUSA
Benson WangFounder & Chairman, HOHO BiotechTaiwan
Liang-Miin Tsai, Prof., M.D.Superintendent, Tainan Municipal HospitalTaiwan
Hsiu-Chih ChouLicensed PharmacistTaiwan
Patents, Certifications & Awards
Global Top 8, Defense Technology category, SelectUSA 2026.
Patent pending — U.S. Patent Application No. 63/675,707 · PCT Application PCT/US2025/037193 (hydrogen-releasing compositions and release-control processes).
- Taiwan FDA Registrations: 3 product registration numbers
- US FDA: 1 registration number
- Health Canada: 1 registration number
- UK FSA: 1 registration number
- Clinical Trial Registrations (ClinicalTrials.gov): NCT05116215 · NCT05196295 · NCT06401785
For further discussion, please feel free to contact us.
GMP- and ISO/HACCP-certified manufacturing; heavy-metal and contaminant testing by SGS and certified third-party laboratories.
Joint translational research initiatives conducted with leading medical universities and clinical trial hospitals in Taiwan and internationally.
Featured by Taiwan Ministry of Economic Affairs (MOEA) press releases and international biotech media for innovation at SelectUSA 2026.
Featured at a rheumatology and immunology press conference held by Tri-Service General Hospital, Taiwan’s largest military hospital and teaching hospital of the National Defense Medical Center (22 April 2026).
Partnership · Investment · Procurement · Distribution
Partnership
We partner with pharmaceutical and vaccine developers to build HRCC into their medicines as an oral adjuvant — helping candidates with toxicity challenges move forward — through licensing, co-development and formulation co-creation. We offer flexible partnership models including proprietary HRCC technology licensing, co-development pipelines, and novel formulation co-creation as a sustainable physiological adjuvant.
View details
- Global pharmaceutical BD and licensing executives.
- Research institutes and university hospitals seeking co-trial partnerships.
- Health & wellness brand owners exploring innovative adjuvant formulation.
- Inquiry Submission
- Initial Technical Review (2–3 business days)
- NDA Execution
- Strategic Working Session
Required Inquiry Info: Proposed partnership model, target application area, and projected development timeline.
Investment
We welcome strategic dialogue with healthcare venture capital firms, corporate venture funds, and family offices aligned with long-term longevity biotech innovations. Detailed investor materials and proprietary data pipelines are shared following standard confidentiality agreements.
View details
- Institutional Biotech & Life Science VCs.
- Healthcare CVCs seeking platform-technology synergy.
- Qualified angel syndicates focusing on deep-tech longevity science.
- Brief Introduction Submission
- Investor Qualification
- Mutual NDA
- Executive Pitch Deck & Financial Overview
Required Inquiry Info: Investor firm profile, investment thesis/focus areas, and whether an executive deck is requested.
Procurement
We supply standardized HRCC capsules and functional ingredients for defense and government programs, clinical research and enterprise manufacturing — including ration-compatible formats for special operations. Every batch ships with a COA, and our GMP manufacturing capacity scales 10–100× within 4–6 months. Our ingredient batches adhere to rigorous quality benchmarks, complete with batch-specific certificates of analysis (COA).
View details
- Supplement and pharmaceutical manufacturers seeking standardized HRCC ingredients for their own formulations
- Nutraceutical and functional food brand manufacturers.
- Specialized institutional, aerospace, or defense resilience procurement units.
- Specification Inquiry
- Technical Documentation & COA Review
- Sample Validation
- Supply Agreement
Required Inquiry Info: Intended product application, estimated volume requirements, and regulatory target regions.
Distribution
HOHO Biotech is expanding our selective global distribution network. We partner with established regional distributors, specialty medical suppliers, and premium longevity centers who demonstrate strong market penetration, educational marketing capabilities, and local regulatory expertise. We also support selected partners in hydrogen inhalation and hydrogen water.
View details
- Regional healthcare and biomedical distributors across North America, Japan, Europe, and Southeast Asia.
- Private medical clinic chains, anti-aging institutes, and functional medicine networks.
- Distribution Application
- Market Evaluation
- Discovery Call & Due Diligence
- Commercial Agreement
Required Inquiry Info: Territory of interest, core distribution channels (clinics, specialty retail, pharmacy), and current brand portfolio.
Contact us
Tell us a little about your inquiry and our team will get back to you.